1. GeneData Solutions in-silico Swapna Annavarapu SoCalBSI CalState, LA

2. Genedata Supporting Drug Discovery with Computational Solutions

3. Mission Statement Genedata develops and markets sophisticated computational solutions for drug discovery related R&D processes

4. Overview Currently 40+ customers with Continuous natural growth 100+ successful projects since 1997 based on consistent performance in revenues Current staff of > 90 Excellent reputation professionals with strong scientific, for quality of computational and business professional services background Strong & innovative Headquarter in Basel, with software portfolio for offices in Boston, San Francisco key research processes

5. Customer List Pharmaceutical Companies Altana, Arrow Therapeutics, Astellas Pharmaceuticals, AstraZeneca, Athelas, Bayer Pharma, Berlex, Merck, Medigene, Millennium, Novartis, Pfizer, Renovis, Roche, Sanofi-Aventis, Serono,Schering, Transtech, Vertex Agrochemical, Biotechnology, and other Life Science Related Companies Bayer CropScience, Bayer Diagnostics, Degussa, diaDexus, Digigenomics, DSM, Masterfoods, MWG-Biotech, Syngenta Research Institutes DKFZ, ETH Zuerich, FMI, National Institutes of Health, NCC Japan, NCC Singapore, NITD Singapore, NITE Japan, University of California, University of Minnesota/Mayo Clinic, University of Muenster

6. Business Model SERVICES + Scientific Consultancy + Technical Consultancy + Custom Development + IT Support LICENSES + Software Systems + Software Modules + Intellectual Property

7. Computational Platform for Drug Discovery

8. The Value Chain

10. Genedata Expressionist®

11. + Corporate-Wide Sample Processing System ¬ Addresses the requirements for integrated support of high-volume data generation (transcriptomics, proteomics, metabolomics) by addressing: integrative data management integrative data analysis & prediction ¬ Key advantages: High-Throughput (experiments & genes/proteins/metabolites) Automation Standardization of data management and data analysis ¬ driving reduction of analysis costs, optimization of quality and thus success rate ¬ Complete process coverage from sample acquisition to decision support ¬ Semantical integration for cross-domain analysis reduces communication overhead within internal organization ¬ Validation according to FDA 21 CFR Part11

12. Product Development Strategy + All products have been developed in close collaboration with major pharmaceuticals since 1997 ¬ Major partners includes: Novartis Altana Schering ¬ Each product is in an advanced stage with > 50 man years of development investment and is ready to install/use ¬ Current versions: Genedata Phylosopher Version 6.0+ Genedata Screener Version 3.0+ Genedata Expressionist Version 6.0+

13. Genedata Success Story + Driving Business Principles for Pharma ¬ Identification of computational needs for important R&D processes (e.g. Biomarker Discovery, In-silico prediction of toxicity and efficacy, uHTS, HCS, Target Validation) ¬ No competitive advantage in internal software development ¬ Most efficient (in terms of TCO) process is implementation and usage of commercial software systems + Case Study Altana ¬ License for Genedata Phylosopher®, Genedata Expressionist® & Genedata Screener® ¬ Custom Development ¬ Development Partner for Genedata Phylosopher® ¬ Scientific Collaborations ¬ Professional Services & Technical Consulting

14. New initiatives + Biomarker Discovery & In-silico Prediction of Toxicity and Efficacy ¬ Increase Prediction Quality (from ~ 10% misclassification to < 1%) Experimental Design SOP Technology Refinement ¬ Genedata as Computational Solution Provider for Innomed Consortium (Focus on Application & FDA requirements) Nugeneris Consortium (Focus on Data Standardization) BioCop Consortium (Focus on SOP & Technology) ¬ Collaboration with customers for FDA 21 CFR Part11 Validation + Systems Biology & Disease Modeling ¬ Understand disease pathways and protein interaction networks ¬ Integration of Transcriptomics, Proteomics & Metabolomics